Teva terminates collaboration with CureTech

Jan 31 2013NewsGuard 100/100 Score

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the termination of its collaboration with CureTech Ltd.

"We are in the process of conducting a disciplined review of our pipeline. As we looked closely at CT-011 and the most recent clinical and biochemical data, we have made the strategic decision to invest our resources elsewhere where we can have the most impact for patients," stated Dr. Michael Hayden, President and CEO of R&D and Chief R&D Officer.

CT-011 is a humanized monoclonal antibody being developed as a treatment for hematological malignancies and solid tumors. CT-011 was assessed in several phase I and II clinical studies in various cancer indications including diffuse large B-cell lymphoma (DLBCL), colon cancer, metastatic melanoma and additional investigator initiated studies.

Teva entered into agreements with CureTech in 2006. Teva intends to book a noncash net charge of $109 million as a result of the impairment of its investment in CureTech.

Source:

Teva Pharmaceutical Industries Ltd.

Posted in: Business / Finance | Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

How different types of bread impact cancer risk
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths
Innovative urine test could improve pancreatic cancer survival rates
Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy
Air pollution linked to head and neck cancer risk
AI-powered tool predicts gene activity in cancer cells from biopsy images
Study shows cannabis as a genotoxic substance with cancer risks
Study shows AI can predict prognosis in triple-negative breast cancer

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Golgi apparatus plays crucial role in enhancing T-cell function against cancer